A monoclonal antibody–drug conjugate targeting B-cell maturation antigen (BCMA) expressed on the surface of MM cells and chimeric antigen receptor (CAR) T-cell therapy targeting BCMA has been approved to treat patients who are refractory to previous treatment strategies (7). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.